What is the recommended treatment for an acute gout flare?

Treatment of Acute Gout Flare

For an acute gout flare, choose corticosteroids, NSAIDs, or colchicine as first-line therapy, with corticosteroids preferred in most patients due to superior safety and lower cost. 1

First-Line Treatment Options

All three medication classes effectively reduce pain in acute gout through anti-inflammatory mechanisms targeting the inflammatory response to urate crystal deposition. 1

Corticosteroids (Preferred First-Line)

Corticosteroids should be considered the initial treatment choice in patients without contraindications because they are generally safer and less expensive than alternatives. 1

• Dosing: Prednisolone 35 mg daily for 5 days has been successfully used to treat acute gout. 1
• Efficacy: Corticosteroids are as effective as NSAIDs for managing gout pain but with fewer adverse effects. 1
• Contraindications: Systemic fungal infections or other known contraindications to corticosteroid use. 1
• Adverse effects: Short-term use carries risks of dysphoria, mood disorders, elevated blood glucose, immune suppression, and fluid retention. 1

NSAIDs (Alternative First-Line)

• Agent selection: No difference exists between different NSAIDs, including indomethacin—naproxen and ibuprofen are equally efficacious despite indomethacin's traditional reputation as the preferred NSAID. 1
• Contraindications: Renal disease, heart failure, or cirrhosis. 1 NSAIDs should be avoided in patients with cardiovascular disease or heart failure. 2
• Adverse effects: Dyspepsia, gastrointestinal perforations, ulcers, and bleeding. 1

Colchicine (Alternative First-Line)

When using colchicine, prescribe low-dose regimens only. 1

• Dosing: 1.2 mg followed by 0.6 mg one hour later. 1
• Efficacy: Low-dose colchicine (1.2 mg then 0.6 mg at 1 hour) is as effective as higher doses (1.2 mg followed by 0.6 mg/hour for 6 hours) but causes fewer gastrointestinal adverse effects. 1
• Cost: Generic colchicine remains more expensive than NSAIDs or corticosteroids. 1
• Contraindications: Renal or hepatic impairment in patients using potent cytochrome P450 3A4 inhibitors or P-glycoprotein inhibitors. 1
• Adverse effects: Diarrhea, nausea, vomiting, cramps, abdominal pain, and infrequently headache and fatigue. 1
• Cardiovascular benefit: Colchicine is safe in patients with cardiovascular disease and may reduce myocardial infarction risk. 2

Initiating Urate-Lowering Therapy During an Acute Flare

You may start allopurinol during an active gout flare if appropriate anti-inflammatory treatment is given concomitantly, rather than waiting for flare resolution. 3

• This represents a paradigm shift from older teaching that required waiting for complete flare resolution. 3
• Mandatory prophylaxis: Initiate concomitant anti-inflammatory prophylaxis (colchicine, NSAIDs, or low-dose prednisone/prednisolone) when starting allopurinol, regardless of whether a flare is present. 3
• Allopurinol dosing: Start at ≤100 mg/day in patients with normal renal function or ≤50 mg/day in chronic kidney disease stage ≥3. 3
• Prophylaxis duration: Continue for a minimum of 3–6 months, with extension if flares persist. 3

Common Pitfalls to Avoid

• Never start allopurinol at 300 mg/day during or after a flare—high initial doses increase both flare risk and allopurinol hypersensitivity syndrome risk. 3
• Do not omit anti-inflammatory prophylaxis when initiating urate-lowering therapy, as this markedly increases early flare rates and treatment discontinuation. 3
• Avoid NSAIDs in patients with cardiovascular disease, heart failure, renal disease, or cirrhosis. 1, 2
• Do not use high-dose colchicine regimens—they offer no additional benefit and cause significantly more gastrointestinal adverse effects. 1

Post-Prophylaxis Flare Risk

After stopping anti-inflammatory prophylaxis, gout flares are common in the immediate three-month period (29.7% of patients experience one or more flares) but subsequently return to baseline levels (12.2%). 4 Patients should be counseled about this increased risk and have a plan for effective gout flare management during this vulnerable period. 4